Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first- line treatment of glioblastoma multiforme (GBM)

被引：0

作者：

Shih, K. C.

Spigel, D. R.

Burris, H. A., III

Brown, R. H.

Shepard, G. C.

Hainsworth, J. D.

机构：

[1] Tennessee Oncol PLLC, Nashville, TN USA

[2] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[3] Sarasota Mem Hosp, Florida Canc Specialists, Sarasota, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2075

引用

页数：1

共 50 条

[31] Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
Lisa BE Shields
Robert Kadner
Todd W Vitaz
Aaron C Spalding
Radiation Oncology, 8
[32] Concurrent Bevacizumab and Temozolomide Alters the Pattern of Failure in Radiation Treatment of Glioblastoma Multiforme
Spalding, A. C.
Wagner, S. A.
Vitaz, T. W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S10 - S10
[33] FINAL RESULTS OF A SINGLE-INSTITUTION PHASE II TRIAL OF RADIATION (RT), TEMOZOLOMIDE (TMZ), ERLOTINIB AND BEVACIZUMAB FOR INITIAL TREATMENT OF GLIOBLASTOMA (GBM)
Clarke, Jennifer
Molinaro, Annette
Phillips, Joanna
Butowski, Nicholas
Chang, Susan
Perry, Arie
Costello, Joseph
DeSilva, Ashley
Rabbitt, Jane
Prados, Michael
NEURO-ONCOLOGY, 2013, 15 : 76 - 76
[34] RANDOMIZED PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB AND IRINOTECAN VERSUS BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY IN NEWLY DIAGNOSED PRIMARY GLIOBLASTOMA MULTIFORME
Hofland, Kenneth F.
Hansen, Steinbjorn
Sorensen, Morten
Schultz, Henrik
Muhic, Aida
Engelholm, Silke
Ask, Anders
Kristiansen, Charlotte
Thomsen, Carsten
Poulsen, Hans S.
Lassen, Ulrik N.
NEURO-ONCOLOGY, 2011, 13 : 51 - 52
[35] Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Hasselbalch, Benedikte
Lassen, Ulrik
Hansen, Steinbjorn
Holmberg, Mats
Sorensen, Morten
Kosteljanetz, Michael
Broholm, Helle
Stockhausen, Marie-Therese
Poulsen, Hans Skovgaard
NEURO-ONCOLOGY, 2010, 12 (05) : 508 - 516
[36] A PHASE II STUDY OF MULTIMODAL THERAPY EMPLOYING SURGERY, CARMUSTINE (BCNU) WAFER, CONCOMITANT TEMOZOLOMIDE AND RADIATION, FOLLOWED BY DOSE DENSE THERAPY WITH TEMOZOLOMIDE PLUS BEVACIZUMAB FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Rezazadeh, Arash
LaRocca, Renato V.
Vitaz, Todd W.
Villanueva, Wayne G.
Hodes, Jonathan
Haysley, Leslie
NEURO-ONCOLOGY, 2011, 13 : 90 - 90
[37] Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
Lou, Emil
Peters, Katherine B.
Sumrall, Ashley L.
Desjardins, Annick
Reardon, David A.
Lipp, Eric S.
Herndon, James E., II
Coan, April
Bailey, Leighann
Turner, Scott
Friedman, Henry S.
Vredenburgh, James J.
CANCER MEDICINE, 2013, 2 (02): : 185 - 195
[38] Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
Peters, Katherine B.
Lou, Emil
Desjardins, Annick
Reardon, David A.
Lipp, Eric S.
Miller, Elizabeth
Herndon, James E., II
McSherry, Frances
Friedman, Henry S.
Vredenburgh, James J.
ONCOLOGIST, 2015, 20 (07): : 727 - 728
[39] Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme.
Hofland, K. F.
Hansen, S.
Sorensen, M.
Schultz, H. P.
Muhic, A.
Engelholm, S.
Ask, A.
Kristiansen, C.
Thomsen, C.
Poulsen, H. Skovgaard
Lassen, U. N.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[40] A PILOT PHASE II TRIAL OF HYPOFRACTIONATED INTENSITY-MODULATED RADIATION THERAPY (hypo-IMRT) COMBINED WITH TEMOZOLOMIDE (TMZ) AND BEVACIZUMAB (BEV) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
Ney, Douglas
Carlson, Julie
Damek, Denise
Blatchford, Patrick
Gaspar, Laurie
Kavanagh, Brian
Waziri, Allen
Lillehei, Kevin
Reddy, Krishna
Chen, Changhu
NEURO-ONCOLOGY, 2013, 15 : 80 - 81

← 1 2 3 4 5 →